Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States.
Ehrenstein V, Huang K, Kahlert J, Bahmanyar S, Karlsson P, Löfling L, Nunes AP, Enger C, Bezemer ID, Kuiper JG, Hoti F, Juuti R, Korhonen P, Mo J, Schachterle SE, Wilner KD, Rørth M, Sørensen HT.
Ehrenstein V, et al. Among authors: schachterle se.
Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):758-769. doi: 10.1002/pds.5193. Epub 2021 Jan 24.
Pharmacoepidemiol Drug Saf. 2021.
PMID: 33428292